Nifty
Sensex
:
:
23850.90
78782.24
-453.45 (-1.87%)
-606.82 (-0.76%)

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 500257 | NSE: LUPIN

1770.20
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1764.05
  •  1785.00
  •  1755.90
  •  1759.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1707589
  •  30228.70
  •  2312.00
  •  1153.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 99,740.18
  • 44.06
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,01,207.55
  • 0.37%
  • 6.66

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.96%
  • 0.32%
  • 5.29%
  • FII
  • DII
  • Others
  • 21.5%
  • 24.10%
  • 1.83%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.59
  • 3.51
  • 6.85

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.46
  • 8.90
  • 77.47

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -2.25
  • 26.17
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.30
  • 38.13
  • 40.83

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.46
  • 3.59
  • 3.81

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.95
  • 17.46
  • 17.86

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Net Sales
5,600.33
4,814.06
16.33%
4,960.79
4,430.08
11.98%
5,197.41
4,322.22
20.25%
5,038.56
4,145.52
21.54%
Expenses
4,359.36
3,957.77
10.15%
3,964.03
3,852.31
2.90%
4,175.45
3,806.18
9.70%
4,120.80
3,692.53
11.60%
EBITDA
1,240.97
856.29
44.92%
996.76
577.77
72.52%
1,021.96
516.04
98.04%
917.76
452.99
102.60%
EBIDTM
22.16%
17.79%
20.09%
13.04%
19.66%
11.94%
18.21%
10.93%
Other Income
67.78
22.83
196.89%
29.34
37.27
-21.28%
45.35
34.59
31.11%
40.40
14.94
170.41%
Interest
68.01
85.67
-20.61%
71.29
92.55
-22.97%
74.01
84.09
-11.99%
80.64
54.88
46.94%
Depreciation
247.71
234.66
5.56%
457.10
263.99
73.15%
257.20
220.40
16.70%
247.85
203.47
21.81%
PBT
993.03
558.79
77.71%
497.71
258.50
92.54%
736.10
246.14
199.06%
629.67
209.58
200.44%
Tax
187.49
105.46
77.78%
129.49
16.11
703.79%
117.40
88.49
32.67%
134.35
75.11
78.87%
PAT
805.54
453.33
77.69%
368.22
242.39
51.91%
618.70
157.65
292.45%
495.32
134.47
268.35%
PATM
14.38%
9.42%
7.42%
5.47%
11.90%
3.65%
9.83%
3.24%
EPS
17.57
9.94
76.76%
7.89
5.19
52.02%
13.46
3.37
299.41%
10.76
2.85
277.54%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
20,797.09
20,010.82
16,641.66
16,405.48
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
Net Sales Growth
17.42%
20.25%
1.44%
8.19%
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
 
Cost Of Goods Sold
6,747.25
5,644.66
6,023.89
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
Gross Profit
14,049.84
14,366.16
10,617.77
10,624.64
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
GP Margin
67.56%
71.79%
63.80%
64.76%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
Total Expenditure
16,619.64
16,221.71
14,921.09
16,190.24
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
Power & Fuel Cost
-
493.07
479.68
443.96
414.48
443.17
442.28
433.88
377.86
381.27
362.81
% Of Sales
-
2.46%
2.88%
2.71%
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
Employee Cost
-
3,494.57
3,087.15
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
% Of Sales
-
17.46%
18.55%
18.22%
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
Manufacturing Exp.
-
2,738.39
2,176.13
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
% Of Sales
-
13.68%
13.08%
13.34%
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
General & Admin Exp.
-
2,221.17
1,733.07
3,490.62
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
% Of Sales
-
11.10%
10.41%
21.28%
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
Selling & Distn. Exp.
-
1,343.30
1,188.72
1,096.10
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
% Of Sales
-
6.71%
7.14%
6.68%
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
Miscellaneous Exp.
-
286.55
232.45
201.43
310.93
1,580.36
192.55
166.20
283.61
204.82
835.48
% Of Sales
-
1.43%
1.40%
1.23%
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
EBITDA
4,177.45
3,789.11
1,720.57
215.24
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
EBITDA Margin
20.09%
18.94%
10.34%
1.31%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
Other Income
182.87
141.58
150.91
213.67
136.29
483.76
333.01
150.35
106.51
185.19
239.75
Interest
293.95
311.61
274.30
142.77
140.64
362.98
302.49
204.35
152.53
59.47
9.81
Depreciation
1,209.86
1,196.81
880.69
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
PBT
2,856.51
2,422.27
716.49
-1,372.57
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
Tax
568.73
486.70
268.80
137.15
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
Tax Rate
19.91%
20.09%
37.52%
-9.99%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
PAT
2,287.78
1,914.48
430.08
-1,528.04
1,215.20
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
PAT before Minority Interest
2,263.53
1,935.57
447.69
-1,509.36
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
Minority Interest
-24.25
-21.09
-17.61
-18.68
-11.40
0.00
0.00
-7.09
-7.17
-8.76
-41.19
PAT Margin
11.00%
9.57%
2.58%
-9.31%
8.01%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
PAT Growth
131.59%
345.15%
-
-
-
-
146.92%
-90.28%
13.00%
-6.13%
 
EPS
50.16
41.98
9.43
-33.50
26.64
-6.00
13.41
5.43
55.89
49.46
52.69

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
14,290.29
12,464.50
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
Share Capital
91.14
91.00
90.90
90.74
90.60
90.50
90.42
90.32
90.12
89.90
Total Reserves
14,084.70
12,224.56
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
Non-Current Liabilities
819.70
992.09
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
Secured Loans
0.00
0.00
141.86
0.33
0.70
358.82
448.03
217.15
5.55
12.50
Unsecured Loans
0.00
27.51
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
Long Term Provisions
375.40
343.03
332.99
329.49
296.29
370.79
356.85
308.73
190.00
162.03
Current Liabilities
8,501.50
9,265.37
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
Trade Payables
2,958.11
2,531.53
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
Other Current Liabilities
1,919.40
1,577.22
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
Short Term Borrowings
2,669.91
4,216.54
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
Short Term Provisions
954.08
940.08
897.12
605.54
1,195.92
771.66
551.23
569.39
325.67
574.26
Total Liabilities
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
Net Block
8,878.30
8,355.24
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
Gross Block
19,664.69
18,077.42
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
Accumulated Depreciation
10,653.98
9,722.18
8,608.68
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
Non Current Assets
10,247.00
10,348.98
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
Capital Work in Progress
772.53
1,237.99
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
Non Current Investment
227.70
77.13
77.60
78.07
36.07
185.63
26.71
22.00
14.33
2.51
Long Term Loans & Adv.
277.52
620.92
572.41
405.79
409.58
402.61
383.00
950.76
960.22
274.20
Other Non Current Assets
90.95
57.70
15.90
12.98
72.95
47.13
9.38
7.96
7.70
0.32
Current Assets
13,447.65
12,451.30
12,457.68
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
Current Investments
846.93
439.77
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
Inventories
4,953.90
4,491.76
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
Sundry Debtors
4,692.05
4,480.70
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
Cash & Bank
1,202.54
1,293.13
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
Other Current Assets
1,752.23
1,519.98
497.54
556.89
1,717.86
1,769.95
1,711.95
1,191.01
1,241.22
534.98
Short Term Loans & Adv.
324.18
225.96
1,146.94
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
Net Current Assets
4,946.15
3,185.93
4,181.24
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
Total Assets
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
3,648.36
1,897.24
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
PBT
2,422.27
716.49
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
Adjustment
1,466.63
1,097.41
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
Changes in Working Capital
85.51
326.52
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
Cash after chg. in Working capital
3,974.41
2,140.42
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-326.05
-243.18
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,712.20
-1,286.77
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
Net Fixed Assets
283.80
-682.44
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
Net Investments
-1,606.34
-463.24
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
Others
-389.66
-141.09
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
Cash from Financing Activity
-2,184.21
-337.25
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
Net Cash Inflow / Outflow
-248.05
273.22
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
Opening Cash & Equivalents
1,231.81
991.37
926.22
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
Closing Cash & Equivalent
983.76
1,264.59
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
311.08
270.67
263.84
300.06
272.01
298.87
295.64
295.04
245.21
196.17
ROA
8.33%
2.01%
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
ROE
14.61%
3.68%
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
ROCE
16.24%
6.06%
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
Fixed Asset Turnover
1.68
1.67
1.93
1.96
2.10
1.93
2.07
1.63
1.80
2.16
Receivable days
52.75
56.09
53.73
64.06
61.62
66.11
63.76
91.82
92.24
72.65
Inventory Days
54.32
58.53
53.64
48.75
42.41
47.94
49.03
71.70
73.96
65.73
Payable days
177.49
144.07
132.55
161.68
65.89
68.49
68.56
60.60
63.20
64.43
Cash Conversion Cycle
-70.43
-29.45
-25.18
-48.88
38.14
45.56
44.23
102.92
103.00
73.94
Total Debt/Equity
0.19
0.34
0.32
0.35
0.51
0.63
0.53
0.60
0.65
0.06
Interest Cover
8.77
3.61
-8.61
12.91
3.40
6.00
3.66
24.18
56.89
349.10

News Update:


  • Lupin launches first generic version of Pred Forte in United States
    15th Oct 2024, 14:26 PM

    Pred Forte had estimated annual sales of $198 million in the U.S. (IQVIA MAT August 2024)

    Read More
  • USFDA completes pre-approval inspection at Lupin’s Biotech facility in Pune
    7th Oct 2024, 09:29 AM

    The inspection was carried out from September 25, 2024 to October 4, 2024, and concluded with five observations

    Read More
  • Lupin inks distribution pact with Scope Ophthalmics
    1st Oct 2024, 11:42 AM

    Through the signature of this collaboration with Lupin, Scope is expanding its footprint in Latin America

    Read More
  • USFDA inspects Lupin’s manufacturing facility at Pithampur Unit-1
    28th Sep 2024, 16:02 PM

    The inspection closed with three observations each on the API and Finished Product side

    Read More
  • Lupin enters into non-exclusive patent license agreement with Takeda
    18th Sep 2024, 14:59 PM

    Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India

    Read More
  • Lupin to make equity investment in Sunsure Solarpark
    11th Sep 2024, 17:18 PM

    The objective of investment is to purchase renewable power through open access for the Company’s Tarapur manufacturing site

    Read More
  • Lupin’s arm recalling 4,554 bottles of Cefixime for Oral Suspension in US market
    5th Sep 2024, 12:12 PM

    Lupin Pharmaceuticals Inc. initiated the Class II recall on August 21

    Read More
  • Lupin launches Mirabegron Extended-Release Tablets in United States
    4th Sep 2024, 15:00 PM

    Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of $1,600 million in the United States

    Read More
  • Lupin’s arm incorporates wholly owned subsidiary in New Zealand
    8th Aug 2024, 14:59 PM

    Lupin NZ will be engaged in the business of pharmaceuticals and pharmaceutical devices in New Zealand

    Read More
  • Lupin reports strong Q1 numbers; consolidated net profit jumps 78%
    7th Aug 2024, 10:41 AM

    Total consolidated income of the company increased by 17.19% at Rs 5,668.11 crore for Q1FY25

    Read More
  • Lupin - Quarterly Results
    6th Aug 2024, 21:03 PM

    Read More
  • Lupin incorporates wholly owned subsidiary in Sri Lanka
    6th Aug 2024, 11:37 AM

    The company will make initial investment of $200,000 in Lupin Lanka

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.